16 May 2024

In this episode of Virtually Live, Shannon Rivkin covers: Probiotec (PBP), Pacific Smiles Group (PSQ), Nick Scali (NCK) and more.

In this week’s show

03:12 – Q1: – PBP, with FIRB approval being granted recently, are there any outstanding conditions remaining (other than shareholder approval)? Also, it mentions there is a permitted dividend of 4 cents which won’t affect the $3 Scheme Consideration payable. Do you think this dividend is likely?

– AND,  the share price dropped from $2.44 to $2.30 on the announcement that the ACCC had suspended the timeline of it’s decision. Is there anything to be concerned about here or is it just that the ACCC have a backlog of reviews similar to a number of recent delays in FIRB decisions?
– PSQ, they are currently trading at the offer price of $1.90. Does this suggest the market is anticipating a competing bid?

 

10:17 – Q2:What are thoughts on the Nick Scali (NCK) capital raising Share Purchase Plan ? Do you think it is worth investing in ?

 

11:52 – Q3:Do you have any links to stat or charts that show the longterm performance of Australian EFTs ? And any advise thereto?

Do you have a question for Shannon?

Send it through and he’ll answer it in the next edition

Continue Reading

Be the first to know. Get the Morning Market Wrap each morning.